23andMe (NASDAQ:ME – Get Rating) released its quarterly earnings results on Thursday. The company reported -0.16 earnings per share for the quarter, missing the consensus estimate of -0.13 by -0.03, Briefing.com reports. The company had revenue of 100.56 million for the quarter, compared to analyst estimates of 102.79 million. The business’s revenue was up 13.5% compared to the same quarter last year. 23andMe updated its FY 2023 guidance to EPS.
ME stock opened at 2.86 on Friday. The firm has a 50 day simple moving average of 3.23 and a two-hundred day simple moving average of 5.18. 23andMe has a one year low of 2.15 and a one year high of 13.68.
Several brokerages have commented on ME. Credit Suisse Group lowered their price objective on shares of 23andMe from $11.00 to $7.00 and set an “outperform” rating on the stock in a research report on Friday. Citigroup lowered their price target on shares of 23andMe from $6.00 to $3.00 and set a “neutral” rating on the stock in a research report on Friday.
23andMe Company Profile (Get Rating)
23andMe Holding Co operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
- Get a free copy of the StockNews.com research report on 23andMe (ME)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.